SCHEMBL4724348

SCHEMBL4724348

CCCOC1(c2cccc3ccccc23)CNCC[N]1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 4/20 0.35
SLC6A3 Q01959 4/20 0.35
SLC6A4 P31645 3/20 0.35
HTR1B P28222 3/20 0.33
MAPT P10636 3/20 0.32
MEN1 O00255 3/20 0.32
KMT2A Q03164 3/20 0.32
NPSR1 Q6W5P4 1/20 0.32
NISCH Q9Y2I1 2/20 0.32
ADRA2A P08913 2/20 0.32
ADRA2B P18089 2/20 0.32
ADRA2C P18825 2/20 0.32
MAPK1 P28482 3/20 0.31
CYP2D6 P10635 2/20 0.31
TAAR1 Q96RJ0 2/20 0.31
LMNA P02545 1/20 0.31
HTR1A P08908 1/20 0.31
ADRA1A P35348 1/20 0.31
OPRM1 P35372 1/20 0.31
PLA2G1B P04054 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4765736 0.93 L3MBTL1 (0.36) SLC6A2SLC6A3SLC6A4HTR1BMAPT
SCHEMBL4724790 0.90 SLC6A3 (0.36) SLC6A2SLC6A3SLC6A4MAPTMEN1
SCHEMBL4765357 0.83 SLC6A3 (0.39) SLC6A2SLC6A3SLC6A4HTR1BMAPT
SCHEMBL4722969 0.82 SLC6A3 (0.44) SLC6A2SLC6A3SLC6A4HTR1BMAPT
SCHEMBL4723127 0.81 SLC6A3 (0.46) SLC6A2SLC6A3SLC6A4HTR1BMAPT
SCHEMBL4720205 0.79 OPRM1 (0.36) OPRM1
SCHEMBL4720403 0.78 SLC6A3 (0.35) SLC6A2SLC6A3SLC6A4HTR1BMAPT
SCHEMBL4723344 0.78 SLC6A3 (0.35) SLC6A2SLC6A3SLC6A4HTR1BMAPT
SCHEMBL4721684 0.75 SLC6A3 (0.42) SLC6A2SLC6A3SLC6A4HTR1BNPSR1
SCHEMBL4722937 0.74 SLC6A3 (0.44) SLC6A2SLC6A3SLC6A4HTR1BNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 SLC6A2 3030/4885SLC6A3 2115/4885SLC6A4 533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.